Enhancement of neointima formation with tissue-type plasminogen activator

Journal of Vascular Surgery

Volumn 33, Issue 4, 2001, Pages 821-828

  Hilfiker, Paul R ^a   Waugh, Jacob M ^a,b   Li Hawkins, Jia J ^b,c   Kuo, Michael D ^a   Yuksel, Eser ^b   Geske, Robert S ^b   Cifra, Pamela N ^b   Chawla, Muneesh ^d   Weinfeld, Adam B ^b   Thomas, John W ^d   Shenaq, Saleh M ^b   Dake, Michael D ^a,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADENOVIRUS; ANIMAL; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL DIVISION; CYTOLOGY; DRUG EFFECT; EXTRACELLULAR MATRIX; FEMORAL ARTERY; GENE TRANSFER; GENE VECTOR; GENETICS; INJURY; INTIMA; MACROPHAGE; NEUTROPHIL; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RABBIT; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANGIOPLASTY, BALLOON; ANIMALS; CD4 LYMPHOCYTE COUNT; CELL DIVISION; EXTRACELLULAR MATRIX; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; NEUTROPHILS; RABBITS; RECOMBINANT PROTEINS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TUNICA INTIMA;

EID: 18044404924     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2001.112323     Document Type: Article

References (38)

1. Cardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1999;337:365-72.
2. Zoldhelyi P, McNatt J, Xu XM, Loose-Mitchell D, Meidell RS, Clubb FJ, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 1996;93:10-7.
3. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-4.
4. Violaris AG, Melkert R, Herrman JR, Serruys PW. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty. Circulation 1994;93:889-97.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
6. Fuster V, Badimon JJ, Chesebro JH, Fallon JT. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996;26 Suppl 4:269-84.
7. Carmeliet P, Bouche A, de Clercq C, Janssen S, Pollefeyt S, Wyns S, et al. Biological effects of disruption of the tissue type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator genes in mice. Ann N Y Acad Sci 1995;748:367-82.
8. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992;2:427-38.
9. Leopold JA, Loscalzo J. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Coron Artery Dis 1995;6:923-9.
10. Garg UC, Hassid A. Nitric oxide (NO) generating vasodilators and 8-bromo-cyclic GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1974-7.
11. Ross R. Growth regulatory mechanisms and formation of the lesions of atherosclerosis. Ann N Y Acad Sci 1995;748:1-6.
12. Holifield B, Helgason T, Jamelka S, Taylor A, Navran S, Allen J, et al. Differentiated vascular myocytes: are they involved in neointimal formation? J Clin Invest 1996;97:814-25.
13. Jang Y, Guzman LA, Lincoff AM, Gottsnauer-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-50.
14. Marks DS, Vita J, Folts JD, Keaney JF, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995;96:2630-8.
15. Moussa I, DiMario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12.
16. GISSI-3 Steering Committee. From GISSI-1 to GUSTO: ten years of clinical trials on thrombolysis. Eur Heart J 1994;15:1155-7.
17. GUSTO Investigators. One year results from the Global Utilization of Streptokinase and tPA for occluded coronary arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.
18. Adams HP, Brott TG, Furla AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke - a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1996;94:1167-74.
19. Rabbani LE, Johnstone MT, Rudd MA, Devine P, George D, Loscalzo J. PPACK attenuates plasmin-induced changes in endothelial integrity. Thromb Res 1993;70:425-36.
20. Crouch MA, Nappi JM. Adjunctive intracoronary thrombolysis in complicated coronary angioplasty. Ann Pharmacother 1997;31:1244-6.
21. Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya P, et al. Rescue Angioplasty in the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial. Am J Cardiol 1997;80:21-6.
22. Ward SR, Sutton JM, Pieper KS, Schwaiger M, Califf RM, Topol EJ. The TAMI Investigators. Effects of thrombolytic regimen, early catheterization and predischarge angiographic variables on six week left ventricular function. Am J Cardiol 1997;79:539-44.
23. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997;81:829-39.
24. Lijnen HR, van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998;18:1035-45.
25. Vassali JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
26. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-36.
27. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 1989;86: 2632-6.
28. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993;82:2414-22.
29. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996;87:1069-78.
30. Li DY, Brooke B, Davis EC, Mecham RP, Sorenson LK, Boak BB. Elastin is an essential determinant of arterial morphogenesis. Nature 1998;393:276-80.
31. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
32. Nusrat AR, Chapman HA. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991;87:1091-7.
33. Rifkin DB, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, et al. Growth factor control of extracellular proteolysis. Cell Differ Dev 1990;32:313-8.
34. Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16 Suppl A:11-5.
35. Waugh JM, Kattash M, Li J, Yuksel E, Kuo MD, Lussier M, et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci U S A 1999;96:1065-70.
36. Waugh JM, Yuksel E, Li J, Kattash M, Saxena R, Geske R, et al. Gene therapy to promote thromboresistance: local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 1999;84:84-92.
37. Waugh JM, Li-Hawkins J, Yuksel E, Kuo MD, Cifra PN, Hilfiker PR, et al. Thrombomodulin overexpression to limit neointima formation. Circulation 2000;102:332-7.
38. Yam LT, Li CY, Crosby WH. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol 1971;55:283-90.